APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Disease Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Respiratory Disease Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025194 pages

Choose your research edition.

Industry ResearchRespiratory Disease Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Disease Vaccine Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Respiratory Disease Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Disease Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Disease Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Respiratory Disease Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Respiratory Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Respiratory Disease Vaccine include Sanofi SA, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., SINOVAC, Serum Institute of India Pvt. Ltd., Novavax, GSK plc. and Emergent BioSolutions Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Disease Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Disease Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Disease Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Disease Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Disease Vaccine Segment by Company

Sanofi SA

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Pfizer Inc.

SINOVAC

Serum Institute of India Pvt. Ltd.

Novavax

GSK plc.

Emergent BioSolutions Inc.

AstraZeneca

Respiratory Disease Vaccine Segment by Type

Live Attenuated

Inactivated

Others

Respiratory Disease Vaccine Segment by Application

Flu

Pneumonia

Others

Respiratory Disease Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Disease Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Disease Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Disease Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Disease Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Respiratory Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Respiratory Disease Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Respiratory Disease Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Respiratory Disease Vaccine Industry Trends Table 2. Respiratory Disease Vaccine Industry Drivers Table 3. Respiratory Disease Vaccine Industry Opportunities and Challenges Table 4. Respiratory Disease Vaccine Industry Restraints Table 5. Global Respiratory Disease Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Respiratory Disease Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Respiratory Disease Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Respiratory Disease Vaccine Sales Market Share by Manufacturers Table 9. Global Respiratory Disease Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Respiratory Disease Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Respiratory Disease Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Respiratory Disease Vaccine Manufacturers, Product Type & Application Table 13. Global Respiratory Disease Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Disease Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Live Attenuated Table 17. Major Manufacturers of Inactivated Table 18. Major Manufacturers of Others Table 19. Global Respiratory Disease Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Respiratory Disease Vaccine Sales by Type (2021-2026) & (K Units) Table 21. Global Respiratory Disease Vaccine Sales by Type (2027-2032) & (K Units) Table 22. Global Respiratory Disease Vaccine Sales Market Share by Type (2021-2026) Table 23. Global Respiratory Disease Vaccine Sales Market Share by Type (2027-2032) Table 24. Global Respiratory Disease Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Respiratory Disease Vaccine Revenue by Type (2021-2026) & (K Units) Table 26. Global Respiratory Disease Vaccine Revenue by Type (2027-2032) & (K Units) Table 27. Global Respiratory Disease Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Respiratory Disease Vaccine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Flu Table 30. Major Manufacturers of Pneumonia Table 31. Major Manufacturers of Others Table 32. Global Respiratory Disease Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Respiratory Disease Vaccine Sales by Application (2021-2026) & (K Units) Table 34. Global Respiratory Disease Vaccine Sales by Application (2027-2032) & (K Units) Table 35. Global Respiratory Disease Vaccine Sales Market Share by Application (2021-2026) Table 36. Global Respiratory Disease Vaccine Sales Market Share by Application (2027-2032) Table 37. Global Respiratory Disease Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Respiratory Disease Vaccine Revenue by Application (2021-2026) & (K Units) Table 39. Global Respiratory Disease Vaccine Revenue by Application (2027-2032) & (K Units) Table 40. Global Respiratory Disease Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Respiratory Disease Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global Respiratory Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Respiratory Disease Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global Respiratory Disease Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Respiratory Disease Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Respiratory Disease Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 49. North America Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 50. Europe Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 52. Europe Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Respiratory Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Respiratory Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global Respiratory Disease Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Respiratory Disease Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Respiratory Disease Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Respiratory Disease Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global Respiratory Disease Vaccine Revenue Market Share by Region (2027-2032) Table 64. Sanofi SA Company Information Table 65. Sanofi SA Business Overview Table 66. Sanofi SA Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sanofi SA Respiratory Disease Vaccine Product Portfolio Table 68. Sanofi SA Recent Development Table 69. Johnson & Johnson Services, Inc. Company Information Table 70. Johnson & Johnson Services, Inc. Business Overview Table 71. Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Portfolio Table 73. Johnson & Johnson Services, Inc. Recent Development Table 74. Merck & Co., Inc. Company Information Table 75. Merck & Co., Inc. Business Overview Table 76. Merck & Co., Inc. Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck & Co., Inc. Respiratory Disease Vaccine Product Portfolio Table 78. Merck & Co., Inc. Recent Development Table 79. Pfizer Inc. Company Information Table 80. Pfizer Inc. Business Overview Table 81. Pfizer Inc. Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Inc. Respiratory Disease Vaccine Product Portfolio Table 83. Pfizer Inc. Recent Development Table 84. SINOVAC Company Information Table 85. SINOVAC Business Overview Table 86. SINOVAC Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. SINOVAC Respiratory Disease Vaccine Product Portfolio Table 88. SINOVAC Recent Development Table 89. Serum Institute of India Pvt. Ltd. Company Information Table 90. Serum Institute of India Pvt. Ltd. Business Overview Table 91. Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Portfolio Table 93. Serum Institute of India Pvt. Ltd. Recent Development Table 94. Novavax Company Information Table 95. Novavax Business Overview Table 96. Novavax Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Novavax Respiratory Disease Vaccine Product Portfolio Table 98. Novavax Recent Development Table 99. GSK plc. Company Information Table 100. GSK plc. Business Overview Table 101. GSK plc. Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. GSK plc. Respiratory Disease Vaccine Product Portfolio Table 103. GSK plc. Recent Development Table 104. Emergent BioSolutions Inc. Company Information Table 105. Emergent BioSolutions Inc. Business Overview Table 106. Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Portfolio Table 108. Emergent BioSolutions Inc. Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca Respiratory Disease Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. AstraZeneca Respiratory Disease Vaccine Product Portfolio Table 113. AstraZeneca Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Respiratory Disease Vaccine Distributors List Table 117. Respiratory Disease Vaccine Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Respiratory Disease Vaccine Product Image Figure 2. Global Respiratory Disease Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Disease Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Respiratory Disease Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Respiratory Disease Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Respiratory Disease Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Live Attenuated Image Figure 9. Inactivated Image Figure 10. Others Image Figure 11. Global Respiratory Disease Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Respiratory Disease Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Respiratory Disease Vaccine Sales Market Share by Type (2021-2032) Figure 14. Global Respiratory Disease Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Respiratory Disease Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Respiratory Disease Vaccine Revenue Market Share by Type (2021-2032) Figure 17. Flu Image Figure 18. Pneumonia Image Figure 19. Others Image Figure 20. Global Respiratory Disease Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Respiratory Disease Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Respiratory Disease Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global Respiratory Disease Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Respiratory Disease Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Respiratory Disease Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Respiratory Disease Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Respiratory Disease Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Respiratory Disease Vaccine Sales Market Share by Country (2021-2032) Figure 40. China Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Respiratory Disease Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Respiratory Disease Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Respiratory Disease Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Respiratory Disease Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Respiratory Disease Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Respiratory Disease Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Respiratory Disease Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Live Attenuated
  • Inactivated
  • Others
Applications
  • Flu
  • Pneumonia
  • Others
Companies covered
  • Sanofi SA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • SINOVAC
  • Serum Institute of India Pvt. Ltd.
  • Novavax
  • GSK plc.
  • Emergent BioSolutions Inc.
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Respiratory Disease Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Respiratory Disease Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Respiratory Disease Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Respiratory Disease Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Respiratory Disease Vaccine Market Dynamics
  1. 2.1 Respiratory Disease Vaccine Industry Trends
  2. 2.2 Respiratory Disease Vaccine Industry Drivers
  3. 2.3 Respiratory Disease Vaccine Industry Opportunities and Challenges
  4. 2.4 Respiratory Disease Vaccine Industry Restraints
3 Respiratory Disease Vaccine Market by Manufacturers
  1. 3.1 Global Respiratory Disease Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Respiratory Disease Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Respiratory Disease Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Respiratory Disease Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Respiratory Disease Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Respiratory Disease Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Respiratory Disease Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Respiratory Disease Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Respiratory Disease Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Respiratory Disease Vaccine Tier 1, Tier 2, and Tier 3
4 Respiratory Disease Vaccine Market by Type
  1. 4.1 Respiratory Disease Vaccine Type Introduction
  2. 4.1.1 Live Attenuated
  3. 4.1.2 Inactivated
  4. 4.1.3 Others
  5. 4.2 Global Respiratory Disease Vaccine Sales by Type
  6. 4.2.1 Global Respiratory Disease Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Respiratory Disease Vaccine Sales by Type (2021-2032)
  8. 4.2.3 Global Respiratory Disease Vaccine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Respiratory Disease Vaccine Revenue by Type
  10. 4.3.1 Global Respiratory Disease Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Respiratory Disease Vaccine Revenue by Type (2021-2032)
  12. 4.3.3 Global Respiratory Disease Vaccine Revenue Market Share by Type (2021-2032)
5 Respiratory Disease Vaccine Market by Application
  1. 5.1 Respiratory Disease Vaccine Application Introduction
  2. 5.1.1 Flu
  3. 5.1.2 Pneumonia
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Disease Vaccine Sales by Application
  6. 5.2.1 Global Respiratory Disease Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Disease Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global Respiratory Disease Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Respiratory Disease Vaccine Revenue by Application
  10. 5.3.1 Global Respiratory Disease Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Respiratory Disease Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global Respiratory Disease Vaccine Revenue Market Share by Application (2021-2032)
6 Global Respiratory Disease Vaccine Sales by Region
  1. 6.1 Global Respiratory Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Disease Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Disease Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Respiratory Disease Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Respiratory Disease Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Respiratory Disease Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Respiratory Disease Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Respiratory Disease Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Respiratory Disease Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Respiratory Disease Vaccine Revenue by Region
  1. 7.1 Global Respiratory Disease Vaccine Revenue by Region
  2. 7.1.1 Global Respiratory Disease Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Respiratory Disease Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Respiratory Disease Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Respiratory Disease Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Respiratory Disease Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Respiratory Disease Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Respiratory Disease Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Respiratory Disease Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Respiratory Disease Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi SA
  2. 8.1.1 Sanofi SA Company Information
  3. 8.1.2 Sanofi SA Business Overview
  4. 8.1.3 Sanofi SA Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi SA Respiratory Disease Vaccine Product Portfolio
  6. 8.1.5 Sanofi SA Recent Developments
  7. 8.2 Johnson & Johnson Services, Inc.
  8. 8.2.1 Johnson & Johnson Services, Inc. Company Information
  9. 8.2.2 Johnson & Johnson Services, Inc. Business Overview
  10. 8.2.3 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Services, Inc. Respiratory Disease Vaccine Product Portfolio
  12. 8.2.5 Johnson & Johnson Services, Inc. Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. Respiratory Disease Vaccine Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Respiratory Disease Vaccine Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 SINOVAC
  26. 8.5.1 SINOVAC Company Information
  27. 8.5.2 SINOVAC Business Overview
  28. 8.5.3 SINOVAC Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 SINOVAC Respiratory Disease Vaccine Product Portfolio
  30. 8.5.5 SINOVAC Recent Developments
  31. 8.6 Serum Institute of India Pvt. Ltd.
  32. 8.6.1 Serum Institute of India Pvt. Ltd. Company Information
  33. 8.6.2 Serum Institute of India Pvt. Ltd. Business Overview
  34. 8.6.3 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Serum Institute of India Pvt. Ltd. Respiratory Disease Vaccine Product Portfolio
  36. 8.6.5 Serum Institute of India Pvt. Ltd. Recent Developments
  37. 8.7 Novavax
  38. 8.7.1 Novavax Company Information
  39. 8.7.2 Novavax Business Overview
  40. 8.7.3 Novavax Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novavax Respiratory Disease Vaccine Product Portfolio
  42. 8.7.5 Novavax Recent Developments
  43. 8.8 GSK plc.
  44. 8.8.1 GSK plc. Company Information
  45. 8.8.2 GSK plc. Business Overview
  46. 8.8.3 GSK plc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK plc. Respiratory Disease Vaccine Product Portfolio
  48. 8.8.5 GSK plc. Recent Developments
  49. 8.9 Emergent BioSolutions Inc.
  50. 8.9.1 Emergent BioSolutions Inc. Company Information
  51. 8.9.2 Emergent BioSolutions Inc. Business Overview
  52. 8.9.3 Emergent BioSolutions Inc. Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Emergent BioSolutions Inc. Respiratory Disease Vaccine Product Portfolio
  54. 8.9.5 Emergent BioSolutions Inc. Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Respiratory Disease Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Respiratory Disease Vaccine Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Disease Vaccine Value Chain Analysis
  2. 9.1.1 Respiratory Disease Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Disease Vaccine Production Mode & Process
  6. 9.2 Respiratory Disease Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Disease Vaccine Distributors
  9. 9.2.3 Respiratory Disease Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst